CA3235099A1 — Method of treating prostate cancer with the gnrh antagonist degarelix
Assigned to Ferring International Center SA · Expires 2009-08-20 · 17y expired
What this patent protects
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for safely and effectively treating androgen-dependent prostate cancer without causing a testosterone spike and/or other side effect of Gn RH agonist therapy such as a urinary …
USPTO Abstract
The invention provides uses and dosing regimens of a gonadotrophin releasing hormone (GnRH) antagonist for safely and effectively treating androgen-dependent prostate cancer without causing a testosterone spike and/or other side effect of Gn RH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.